Search

Search Constraints

You searched for: Author/Creator Fornarini, Giuseppe

Search Results

1. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study. (20th November 2020)

2. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. (February 2022)

4. BRCA1 and BRCA2 Gene Mutations in Breast/Ovarian Cancer Patients from Central and Southern Italy. Issue 1 (17th June 2013)

5. Cabozantinib‐related cardiotoxicity: a prospective analysis in a real‐world cohort of metastatic renal cell carcinoma patients. Issue 6 (31st March 2019)

6. Cardiovascular risk profile and events before and after treatment with anti-VEGF drugs in the setting of a structured cardio-oncologic program. (7th May 2020)

7. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. Issue 3 (24th February 2012)

9. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study. (20th March 2022)

10. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status. (February 2023)